Notice: This company has been marked as potentially delisted and may not be actively trading. BioTelemetry (BEAT) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends Get the Latest News and Ratings for BEAT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for BioTelemetry and its competitors. Enter your email to sign up for newsletter Sign Up BEAT Analyst Ratings Over TimeTypeCurrent Forecast3/12/24 to 3/12/251 Month Ago2/11/24 to 2/10/253 Months Ago12/13/23 to 12/12/241 Year Ago3/13/23 to 3/12/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$8.00$8.00$8.00$6.78Forecasted Upside284.62% Upside235.43% Upside162.30% Upside192.03% UpsideConsensus RatingBuyBuyBuyBuy Remove Ads BEAT Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History BEAT Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table BioTelemetry Stock vs. The CompetitionTypeBioTelemetryMedical CompaniesS&P 500Consensus Rating Score 3.00 2.82 2.53Consensus RatingBuyModerate BuyModerate BuyPredicted Upside279.33% Upside26,027.01% Upside20.71% UpsideNews Sentiment RatingNeutral NewsSee Recent BEAT NewsPositive NewsPositive News Remove Ads Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails11/15/2024Benchmark2 of 5 starsW. SutherlandSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$8.00 ➝ $8.00+252.42%5/19/2023Alliance Global Partners1 of 5 stars Lower Target$10.00 ➝ $5.55+151.13%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:58 PM ET. BEAT Forecast - Frequently Asked Questions What is BioTelemetry's forecast for 2025? According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for BioTelemetry is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. Should I buy or sell BioTelemetry stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BEAT shares. Does BioTelemetry's stock price have much upside? According to analysts, BioTelemetry's stock has a predicted upside of 284.62% based on their 12-month stock forecasts. Do Wall Street analysts like BioTelemetry more than its competitors? Analysts like BioTelemetry more than other "medical" companies. The consensus rating for BioTelemetry is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BEAT compares to other companies. Stock Forecasts and Research Tools Related Companies NVRO Stock Forecast RCEL Stock Forecast PROF Stock Forecast DRTS Stock Forecast BWAY Stock Forecast CATX Stock Forecast SKIN Stock Forecast LNSR Stock Forecast OBIO Stock Forecast PDEX Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:BEAT) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioTelemetry, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioTelemetry With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BEAT Stock Alerts